LLY Eli Lilly and Company March 16, 2026 RBC Maintains Outperform

RBC Capital maintained an Outperform rating on Eli Lilly and Company (LLY) on March 16, 2026. The LLY analyst rating cites the pending Orfo approval and the drug’s potential launch as the key driver. RBC’s note keeps LLY in a favorable view even as markets weigh near-term catalysts. The update reported a price movement of 0.77% ($7.52) since the prior note. Meyka AI provides real-time context and tracks how this LLY analyst rating connects to price and consensus.